Gastric Cancer Drugs Market – By Therapy Type (Kinase Inhibitors, Nucleoside Metabolic Inhibitors, Microtubule Inhibitors, VEGF Antibodies, Her2 Receptor Antagonists, And Car T Cell Therapy), By Route Of Administration (Oral And Parenteral), By Application (Adenocarcinomas, Gastrointestinal Stromal Tumors, And Carcinoid Tumors), By End User (Hospital, Retail Pharmacy, And Online Pharmacy) and By Region - Global Opportunity Analysis and Industry Forecast, 2020 – 2030

DFS020190  | 
: Life Sciences & Healthcare  | 
Mar-2024  | 
Upcoming  | 
Pages: NA  | 
Tables: NA  | 
Figures: NA
We’ve been tracking the direct impact of COVID-19 on this market, as well as the indirect impact from other industries. The report will incorporate these insights.

Gastric Cancer Drugs Market accounted approximate USD 3.6 billion in 2020 and it is expected to reach USD 13.3 billion by 2030 with a CAGR of 13.80% during forecast period.Gastric cancer is the formation of abnormal cells on the inner lining of stomach resulting into stomach tumors. Additionally, Gastric cancer is also known as stomach cancer and gastric cancer drugs are used to treat malignancies or cancerous cells growth. According to report it is identified that gastric cancer was responsible for fourth most common malignancy occur in men and seventh rank in women. Additionally, treatment cancer is depends upon the stage of cancer and there are number of treatments available for the cancer such as chemo therapy, radiation therapy, surgery and others.

Market Segmentation:

On the basis of therapy type, the gastric cancer drugs market is segmented into kinase inhibitors, nucleoside metabolic inhibitors, microtubule inhibitors, VEGF antibodies, HER2 receptor antagonists, and car T cell therapy. Based on route of administration it is bifurcated into oral and parenteral. On the basis of application type it is classified into adenocarcinomas, gastrointestinal stromal tumors, and carcinoid tumors. On the basis of end user type it is segmented into hospital, retail pharmacy, and online pharmacy. Based on region it is segmented into North America, Asia Pacific, Europe, Latin America and Middle East & Africa.

Market Dynamics and Factors:

Rising incidence and prevalence rate of gastric cancer are boosting the global gastric cancer drugs market. Moreover, increasing in R&D studies and clinical trials to understand stomach cancer better and to develop medicine are highly contributing to the gastric cancer drugs market revenue. Additionally, increase in smoking population, obesity cases, consuming tobacco, unhealthy diet lifestyles resulting into the increase in number of cases in gastric cancer will drive the growth for gastric cancer drug market. However, high cost involved in the treatment and side effects due to prolonged use of cancer drugs hinders the growth of market. Moreover, the development of innovative drugs and rising awareness about these treatments among the consumers can be opportunity for the gastric cancer drugs market.

Geographic Analysis:

North America is dominating the gastric cancer drugs market and is anticipated to maintain same trend during the forecast period. According to research study, guidelines of medicines regulatory agencies in the region are driving the market. Moreover, availability of better medical infrastructure, increase in R&D, availability of drug development therapies in the region driving the market for gastric cancer drugs. Asia Pacific is anticipated to witness fastest growth and is expected maintain same trend during forecast period. According, to research report the region generated approximate USD 1.12 billion revenue in 2018. Rise in incidences of gastric cancer in the region primarily in India and China are driving the growth of market. The World Health Organization (WHO) estimates that China accounted approximate 456,124 gastric cancer cases in 2018.

Competitive Scenario:

Some of the key players in global gastric cancer drugs market are F. Hoffmann-La Roche ltd., Novartis A.G., Eli Lily and company, Sanofi S.A., Bayer A.G., Otsuka pharmaceuticals co.Ltd., Gilead Sciences Inc., Celltrion Inc., Taiho pharmaceuticals co. ltd, and Merck & co. Inc.

Gastric Cancer Drugs Market Report Scope

Report Attribute

Details

Analysis Period

2020–2030

Base Year

2021

Forecast Period

2022–2030

Market Size Estimation

Billion (USD)

Growth Rate (CAGR%)

13.8 %

Market Segmentation:

By Therapy Type (Kinase Inhibitors, Nucleoside Metabolic Inhibitors, Microtubule Inhibitors, VEGF Antibodies, Her2 Receptor Antagonists, And Car T Cell Therapy), By Route Of Administration (Oral And Parenteral), By Application (Adenocarcinomas, Gastrointestinal Stromal Tumors, And Carcinoid Tumors), By End User (Hospital, Retail Pharmacy, And Online Pharmacy)

Geographical Segmentation

North America (U.S., Canada, Mexico) Europe (UK, Germany, Italy, France, Rest of Europe), Asia-Pacific (China, Japan, India, Australia, Rest of APAC), South America (Brazil, Argentina, Rest of SA), MEA (UAE, Saudi Arabia, South Africa)

Key Companies Profiled

F. Hoffmann-La Roche ltd., Novartis A.G., Eli Lily and company, Sanofi S.A., Bayer A.G., Otsuka pharmaceuticals co.Ltd., Gilead Sciences Inc., Celltrion Inc., Taiho pharmaceuticals co. ltd, and Merck & co. Inc.      

 


TOC REQUEST


KEY MARKET SEGMENTS:

  • Global Gastric Cancer Drugs Market – By Therapy Type
    • Kinase Inhibitors
    • Nucleoside Metabolic Inhibitors
    • Microtubule Inhibitors
    • VEGF Antibodies
    • Her2 Receptor Antagonists
    • Car T Cell Therapy
  • Global Gastric Cancer Drugs Market – By Route of Administration
    • Oral
    • Parenteral
  • Global Gastric Cancer Drugs Market – By Application
    • Adenocarcinomas
    • Gastrointestinal Stromal Tumors
    • Carcinoid Tumors
  • Global Gastric Cancer Drugs Market – By End-User
    • Hospital
    • Retail Pharmacy
    • Online Pharmacy
  • Global Gastric Cancer Drugs Market – By Geography
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • U.K.
      • France
      • Germany
      • Italy
      • Rest of Europe
    • Asia-Pacific
      • Japan
      • China
      • India
      • Australia
      • Rest of Asia Pacific
    • ROW
      • Latin America
      • Middle East
      • Africa

KEY PLAYERS
o    F. Hoffmann-La Roche ltd.
o    Novartis A.G.
o    Eli Lily and company
o    Sanofi S.A.
o    Bayer A.G.
o    Otsuka pharmaceuticals co. Ltd.
o    Gilead Sciences Inc.
o    Celltrion Inc.
o    Taiho pharmaceuticals co. ltd
o    Merck & co. Inc.


 
©2024 Decision Foresight. All Rights Reserved.